Eris Lifesciences Limited concluded its 20th Annual General Meeting on September 25, 2026, adopting the audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026. The meeting, conducted via Video Conferencing, also ratified the remuneration of cost auditors for FY27 and approved director reappointments.

Key resolutions passed

The shareholders transacted the following business items through remote e-voting in accordance with applicable laws:

• Adoption of Audited Standalone and Consolidated Financial Statements for FY26, along with Board and Auditor reports.
• Appointment of Kaushal Kamlesh Shah (DIN: 01229038) as a director in place of himself, who retired by rotation and offered himself for reappointment.
• Ratification of the remuneration of Cost Auditors for the Financial Year ending March 31, 2027.
• Reappointment of Sujesh Vasudevan (DIN: 08240092) as an Independent Director of the company.

Governance and compliance details

The proceedings were conducted in compliance with Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results of the voting on these resolutions will be disclosed to the stock exchanges separately as required under Regulation 44(3) of the same regulations.

The Annual General Meeting commenced at 11:00 am and concluded at 11:30 am. Milind Talegaonkar, Company Secretary and Compliance Officer, signed the proceedings digitally on September 25, 2026.

Eris Lifesciences has appointed Akhil Awasthi as an additional non-executive, independent director. The appointment is effective from September 26, 2026.

The Board of Directors approved the move on September 21, 2026, based on the recommendation of the Nomination and Remuneration Committee. The decision was formalized through a circular resolution issued the same day.

Appointment Details

Mr. Awasthi will serve a term of five years. His appointment as an Additional Director is subject to the approval of the company’s members at a general meeting.

Profile and Governance

Mr. Awasthi brings over three decades of experience in private equity, investment management, healthcare, and corporate governance. He previously served as Founding Managing Partner and Investment Committee Member of Tata Capital Growth Fund. He also held the position of Partner at Baring Private Equity Partners (India) Ltd.

The filing confirms that Mr. Awasthi is not related to any existing director of the company. He is not debarred from holding the office of Director by SEBI or any other authority. The disclosure was made pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.